A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.
A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.
复制标题
DOI：
10.1016/j.biopha.2020.111037
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Su YC
中科院分区：
文献类型：
--
作者：
Tsai KC;Huang YC;Liaw CC;Tsai CI;Chiou CT;Lin CJ;Wei WC;Lin SJ;Tseng YH;Yeh KM;Lin YL;Jan JT;Liang JJ;Liao CC;Chiou WF;Kuo YH;Lee SM;Lee MY;Su YC
新冠肺炎是一场全球性疫情，截至2020年11月11日，已有5000多万确诊病例，120万人死亡。到目前为止，还没有推荐任何治疗或疫苗来治疗或预防这种新的冠状病毒。自2020年4月以来，一种新的中药配方--台湾清关一号(NRICM101)已被用于台湾新冠肺炎患者。它的临床结果和药理学已经被评估。在两个医疗中心收治的33名确诊为新冠肺炎的患者中，那些年龄较大、病情较重、合并疾病较多且住院21天后没有改善的患者(n = 12)接受了NRICM101治疗。他们在9天的中位数内连续3次取得阴性结果，并且没有报告任何不良事件。药理实验表明，该方可抑制纤突蛋白/血管紧张素转换酶2相互作用、3CL蛋白酶活性、病毒空斑形成、细胞因子IL-6和肿瘤坏死因子-α的产生。这项床边研究表明，NRICM101可能通过其抗病毒和抗炎特性阻止疾病进展，有望成为预防和治疗新冠肺炎的多靶点制剂。
COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020. Its clinical outcomes and pharmacology have been evaluated. Among 33 patients with confirmed COVID-19 admitted in two medical centers, those (n = 12) who were older, sicker, with more co-existing conditions and showing no improvement after 21 days of hospitalization were given NRICM101. They achieved 3 consecutive negative results within a median of 9 days and reported no adverse events. Pharmacological assays demonstrated the effects of the formula in inhibiting the spike protein/ACE2 interaction, 3CL protease activity, viral plaque formation, and production of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α. This bedside-to-bench study suggests that NRICM101 may disrupt disease progression through its antiviral and anti-inflammatory properties, offering promise as a multi-target agent for the prevention and treatment of COVID-19.